Targeting Protein-DNA Interactions in the DNA Damage Response: Lead Identification & Optimization for Novel Inhibitors of Replication Protein A (RPA) & Ku

Time: 11:30 am
day: Day Two


  • Understanding how NERx is positioned to lead the first-in-class and first-in-human trials of novel agents targeting RPA and Ku
  • Delving into how RPAi’s synergy with DNA damage-inducing therapeutics and DDR targeted therapies, and a lead candidate has been selected
  • Exploring Ku inhibitors blockage of the Ku-DNA interaction and serve as a novel approach to inhibit DNA-PK